Seres Therapeutics MCRB 深 滬
等待開盤 08-21 09:30:00 美东时间
4.57
-0.110
-2.35%
華盛通- 最 高4.69
- 今 開4.64
- 成交量 7.45万股
- 最 低 4.39
- 昨 收 4.68
- 總市值 4590.46万
- 52周最高 29.98
- 市盈率 靜 7.12
- 換手率 0.74%
- 52周最低 4.315
- 委 比 43.47%
- 總股本 1004.48万
- 歷史最高 1040.00
- 量 比 1.16
- 振 幅 6.41%
- 歷史最低 4.315
- 每 手 1
- 風險率 5.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
SERES THERAPEUTICS, INC. $300,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the se...
08-14 05:21
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share from the same period last year. The company reported quarterly sales of $736.000 t...
08-05 19:29
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes
Seres Therapeutics ( ($MCRB) ) has issued an update. On July 31, 2026, Seres Th...
08-05 04:30
Seres Therapeutics reports positive SER-155 trial results
Seres Therapeutics ( ($MCRB) ) has provided an announcement. On July 8, 2026, S...
07-08 20:30
Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed
The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases, evaluated SER-155 in 15 patients with moderate-to-severe (Grade 2- 3) irEC, which affects approximately 25% of all immune checkpoint inhibitor (ICI) th...
07-08 19:04
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Seres Therapeutics announced positive top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC). In the trial conducted at Memorial Sloan Kettering Cancer Center (MSK), 80% of participants achieved an immunosuppressive-free clinical response at Day 15, with no serious adverse events related to SER-155 observed. The drug demonstrated robust engraftment a...
07-08 11:00
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
06-23 19:29
